LLY vs ABBV
By Alex · Tickerpine
Eli Lilly and Company vs AbbVie Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | ABBV |
|---|---|---|
| Price | $1,233.66 | $265.79 |
| Market cap | $1.10T | $469.68B |
| P/E ratio | 41.8 | 74.7 |
| ROE | 102.29% | — |
| Profit margin | 33.53% | 9.80% |
| Revenue growth | 47.70% | 10.20% |
| Dividend yield | 0.55% | 2.62% |
| Beta | 0.51 | 0.28 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs ABBV in plain English
- LLY is the bigger company — about 2.3× the market cap of ABBV.
- LLY is cheaper on earnings (P/E 41.8 vs 74.7).
- LLY is growing revenue faster (48% vs 10%).
- ABBV has the higher dividend yield (2.62% vs 0.55%).
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
ABBV return calculator
See what $1,000 in AbbVie Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.